

ACADEMIC JOURNAL OF HEALTH SCIENCES

MEDICINA BALEAR

Detection of virulence factors amongst the *Vibrio parahaemolyticus* strains isolated from marine food samples caught from the Persian Gulf

Assessment of cardiometabolic status in 5.994 german mechanics

Relationship between healthy habits and sociodemographic variables in the values of different atherogenic indices

Classification of blood pressure with JNC-7 criteria in spanish working population: influence of age, sex, social class and tobacco consumption

Determination of different scales of cardiovascular risk in 1.979 spanish informatics workers

Variables that influence the degree of control in dyslipidemic patients under hypolipidemic treatment

Risk factors associated with the use and consumption of drugs in students of the Higher Technological Institute Sucre

Results of arthroscopic debridement in patients with osteoarthritis of the knee

Evaluation of King's variceal prediction score as a marker of portal hypertension in children with chronic liver diseases

Investigating the effect of ORS with probiotics, zinc and vitamin A on children's diarrhea: a randomized clinical trial

Drug use evaluation of oral hypoglycemics in diabetic patients in a tertiary care hospital, India

Designing a competency model for managers of health care networks in Iran

Intramammary lymph nodes, clinical characteristics and prevalence

Preparation and implementation of standard therapeutic guidelines for poisoning cases in a tertiary care hospital, Mysuru, India

Anthropometric profile in 1.350 well being and beauty professionals

Sociodemographic variables influencing the prevalence of insulin resistance in the italian population

Relationship between blood pressure levels and body mass index values in 41,093 ukrainians people

The epidemiological and preventive situation in Spain of causal human papilloma virus cancers

The role of environmental factors and molecular genetics diagnosis in treatment of breast cancer in Iran, Qom (2019-2020)

Relationship between different scales related to cardiovascular risk and Finrisk test values in workers

Prevalence of overweight and obesity in spanish working population along the Covid-19 pandemic. Adiposity indicators and related variables

Effect of a *Coriolus versicolor*-based vaginal gel on cervical epithelialization and vaginal microbiota in HPV-positive women: EPICERVIX pilot study

Evaluation the effectiveness of the cognitive rehabilitation therapy model for improvement executive functions in high- functions autistic children, by using neuroimaging, neuropsychological and molecular genetics technique

The study of gestational diabetes as a silent disease

The headquarters of the Royal Academy of Medicine of the Balearic Islands (1830-2022)

Ozone therapy, scientific support and use as complementary therapy in COVID-19

Orbital lymphoma. Presentation of a small series

Learning disability; the tip of the iceberg

ACADEMIC JOURNAL OF HEALTH SCIENCES

www.medicinabalear.org

Academic Journal of Health Sciences Medicina Balear is the organ of the **Royal Academy of Medicine of the Balearic Island**, It was created in 1986 with the aim of following up the scientific concerns and promoting the research spirit of health professionals in the Balearic Islands and with the additional objective of projecting health issues of interest to society.

Currently **Academic Journal of Health Sciences Medicina Balear** publishes in English, Spanish or Catalan original papers, review articles, letters to the editor and other writings of interest related to health sciences. The journal submits the originals to the anonymous review of at least two external experts (peer review).



The scientific material published in **AJHS Medicina Balear** is protected by copyright. **AJHS Medicina Balear** is not responsible for the information and opinions of the authors.

This work-unless otherwise indicated in the text, photographs, or other illustrations-is licensed under the Creative Commons NonCommercial-NoDerivativeWorks 3.0 Spain license.

Creative Commons; <http://creativecommons.org/licenses/by-nc-nd/3.0/es/>. In addition, the general public is authorized to reproduce, distribute and communicate the work provided that the authorship and the publishing entity are acknowledged and that no commercial use or derivative work is made.

Medicina Balear is included in the Digital Library of the Balearic Islands, of the University of the Balearic Islands, and is included in the following databases: Emerging Sources Citation Index (ESCI), Sherpa Romeo, Dulcinea, Latindex (catàleg), Dialnet, Índice Médico Español, DOAJ, Imbiomed, REDIB, Google Scholar and Journal Citation Indicator (JCI).



Biblioteca digital de les
Illes Balears



Universitat
de les Illes Balears



Clarivate
Analytics

WEB OF SCIENCE™

SHERPA
RoMEO

DOAJ DIRECTORY OF
OPEN ACCESS
JOURNALS



DULCINEA
CONDICIONES DE AUTO-ARCHIVO DE
LAS REVISTAS CIENTÍFICAS ESPAÑOLAS

latindex IME

Índice
Médico
Español



Dialnet



CSIC
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS

Google Scholar



EDIT

Royal Academy of Medicine of the Balearic Islands



www.ramib.org

Campaner, 4, 07003 Palma de Mallorca Tel. 971 72 12 30 Email: info@ramib.org

Pàgina web: <http://www.ramib.org>

Dipòsit Legal: PM 486 - 95

eISSN: 2255 - 0569

Design and layout

Inteligencia Publicitat - www.inteligencia.es - inteligencia@inteligencia.es

ACADEMIC JOURNAL OF HEALTH SCIENCES

Three-monthly journal of the Royal Academic of Medicine
of the Balearic Island

Editor A. Arturo López González, *RAMIB*,
Reial Acadèmia de Medicina de les Illes Balears (*RAMIB*)

EDITORIAL COUNCIL

Assistant manager Joan March Noguera, *RAMIB*
Scientific editor Marta Couce Matovelle, *Case Western Reserve University*
Editorials consultings José A. Guijarro Pastor, *AEMET* · Jaume Rosselló Mir, *UIB*
Editor-in -chief J. L. Olea Vallejo, *RAMIB*
Vowels Antoni Aguiló Pons, *Universitat de les Illes Balears* · Antonia Barceló Bennassar, *Hospital Son Espases* · Bartolomé Burguera González, *Cleveland Clinic (Ohio)* · Amador Calafat Far, *Socidrogalcohol* · Carlos Campillo Artero, *Universitat Pompeu Fabra* · Valentín Esteban Buedo, *Conselleria de Sanitat, Generalitat Valenciana* · Carmen González Bosch, *Universitat de València* · Miguel A. Limon Pons, *Institut Menorquí d'Estudis* · Jordi Martínez Serra, *Hospital Son Espases* · Virgili Páez Cervi, *Bibliosalut* · Lucio Pallarés Ferreres, *Hospital Son Espases* · Ignacio Ricci Cabello, *University of Oxford* · Guillermo Sáez Tormo, *Universitat de València* · M^a Teófila Vicente Herrero, *IUNICS*

SCIENTIFIC COUNCIL

M^a José Anadón Baselga (*Universidad Complutense de Madrid*), Miquel Capó Martí (*Universidad Complutense de Madrid*), Antonio Coca Payeras (*Universitat de Barcelona*), James Drane (*Edinboro University*), Leopoldo Forner Navarro (*Universitat de València*), Alexandre García-Mas, (*Universitat de les Illes Balears*), Antoni Gelabert Mas (*Universitat Autònoma de Barcelona*), Joan Grimalt Obrador (*Consell Superior d'Investigacions Científiques, CSIC*), Federico Hawkins Carranza (*Universidad Complutense de Madrid*), Joan Carles March Cerdà (*Escuela Andaluza de Salud Pública, EASP*), Gabriel Martí Amengual (*Universitat de Barcelona*), Jasone Monasterio Aspiro (*Universitat Autònoma de Barcelona*) Rosa Pulgar Encinas (*Universidad de Granada*), Ciril Rozman (*Universitat de Barcelona*), Joan Benejam Gual (*Hospital de Manacor*), Joan Llobera Cànaves (*Atenció Primària - Mallorca*), José Reyes Moreno (*Hospital de Inca*), José María Vicens Colom (*Cercle d'Economia de Mallorca*), Carmen Tomás-Valiente Lanuza (*UIB*), Antonio Pareja Bezares (*Conselleria de Salut*), Farhad Safarpour Dehkordi (*Tehran University*), Anton Erkoreka Barrena (*Director del Museo Vasco de Historia de la Medicina y de la Ciencia*), José Ignacio Ramírez Manent (*Atención Primaria de Mallorca-Facultad de Medicina UIB*), Colwyn M. Jones (*European Association of Dental Public Health*), Pål Barkvoll (*Universitetet i Oslo*), Teresa Szupiany-Janeczek (*Jagiellonian University Medical College Krakow*), Yarmukhamedov Bekhzod (*Tashkent University*), Dr. Pablo Arsenio López (*Director de LA PRENSA MÉDICA ARGENTINA*), Manuel Luis Martí (*Academia Nacional de Medicina de Buenos Aires*), Jesús Yasoda Endo Milán (*Universidad de Ciencias Médicas de Villa Clara. Cuba*), Manel Gené Badia (*Universidad de Barcelona*), Pedro Juan Tàrraga López (*Universidad de Castilla la Mancha*), Natalia Tretiak (*Poltava Ukrainian Medical & Stomatological Academy*), Petro Tretiak Kravchuk (*Poltava Ukrainian Medical & Stomatological Academy*), Hans A Eguía (*Dansk Selskab for Almen Medicin-DSAM*).

With the collaboration



G CONSELLERIA
O PRESIDÈNCIA,
I FUNCIO PÚBLICA
B IIGUALTAT

Fundació
Patronat Científic



Col·legi de Metges
Illes Balears

ORIGINAL

Effect of a *Coriolus versicolor*-based vaginal gel on cervical epithelialization and vaginal microbiota in HPV-positive women: EPICERVIX pilot study

Eficacia de un gel vaginal basado en Coriolus versicolor sobre la epitelización cervical y la microbiota vaginal en mujeres positivas al VPH: Estudio piloto EPICERVIX

**Silvia González¹ , Luís Serrano¹ , Javier Cortés² , Teresa Vezza^{3,4} ,
José Garrido-Mesa³ , Francesca Algieri³ , Rocío Morón^{3,5} ,
Maria Elena Rodríguez Cabezas^{3,4} , Julio Gálvez^{3,4} , Alba Rodríguez Nogales^{3,4,6} **

1. Department of Gynaecology, Policlínico HM Gabinete Velázquez, Madrid, Spain. 2. Cytopathology. Oncological Gynaecology, Private Practice, Palma, Spain. 3. CIBER-EHD, Department of Pharmacology, Centre for Biomedical Research (CIBM), University of Granada, 18071-Granada, Spain. 4. Instituto de Investigación Biosanitaria de Granada (Ibs.GRANADA), Granada, Spain.

5. Department of Hospital Pharmacy. Hospital Universitario Clínico San Cecilio. Granada, Spain.

6. Department of Gastrointestinal Medicine, Hospital Universitario Virgen de las Nieves, 18012-Granada, Spain.

Corresponding author

Teresa Vezza PhD

Department of Pharmacology

Centre for Biomedical Research, University of Granada

Avenida del Conocimiento S/N, 18016-Armilla, Granada, Spain

E-mail: teresavezza@hotmail.it

Received: 21 - XII - 2021

Accepted: 17 - II - 2022

doi: 10.3306/AJHS.2022.37.02.139

Abstract

Objectives: A *Coriolus versicolor*-based vaginal gel (Papilocare®) has been shown to speed up the cervicovaginal mucosa epithelialization and a tendency to improve the composition of the microbiota in healthy women. The study aimed to evaluate the effects of this gel on cervical epithelialization and composition of vaginal microbiota in HPV-positive women with normal cytology and colposcopy.

Methods: A total of 21 HPV-positive women with negative Papanicolaou smear and normal colposcopy were once-daily treated with Papilocare® for 21 days. At baseline and the end of treatment, degree of epithelialization of the cervix mucosa was evaluated by colposcopy (and rated by the five-point Likert scale), and vaginal microbiota composition was analysed by next-generation sequencing.

Results: At the end of treatment, cervix epithelialization was improved in 52.6% of women. The treatment produced a statistically significant reduction in phylogenetic diversity. Moreover, abundance in *Proteobacteria* phylum was reduced (38.5% vs 93.6% at baseline) while increased in *Firmicutes* phylum (44.6% vs 2.1%). A significant increase and reduction in the proportion of *Lactobacillus* spp. Beij. (*Lactobacillaceae* family), including *L. crispatus* and *L. iners*, and *Gardnerella vaginalis* was reported, respectively.

Conclusions: The application of the *Coriolus versicolor*-based vaginal gel significantly improved ectocervix epithelialization and the vaginal microbiota composition among HPV-positive women without cervical lesions, which could support its use for preventing HPV-associated cervix lesions.

Keywords: Cervix epithelialization, human papillomavirus, *Lactobacillus*, Papilocare, vaginal microbiota, *Coriolus versicolor*.

Resumen

Objetivos: Un gel vaginal basado en *Coriolus versicolor* (Papilocare®) ha mostrado acelerar la epitelización de la mucosa cervicovaginal y una tendencia a mejorar la composición de la microbiota en mujeres sanas. El estudio fue diseñado para evaluar los efectos de este gel sobre la mucosa cervicovaginal y la composición de la microbiota de mujeres VPH positivas con citología y colposcopia normales.

Métodos: Un total de 21 mujeres fueron tratados una vez al día con Papilocare® durante 21 días. En el momento basal y al final del tratamiento, se evaluó el grado de epitelización de la mucosa cervical mediante colposcopia (y se cuantificó mediante una escala Likert de cinco puntos) y se analizó la composición de la microbiota vaginal mediante tecnologías nuevas de secuenciación.

Resultados: Al final del tratamiento, la epitelización de la mucosa cervical mejoró en el 52.6% de las mujeres. El tratamiento produjo una reducción estadísticamente significativa en la diversidad filogenética. Además, se redujo la abundancia de *Proteobacteria* phylum (38.5% vs 93.6% en el momento basal), mientras que se incrementó la de *Firmicutes* phylum (44.6% vs 2.1%). Se observó un aumento y disminución significativa de las proporciones de *Lactobacillus* spp. Beij. (familia *Lactobacillaceae*), incluyendo *L. crispatus* and *L. iners*, y de *Gardnerella vaginalis*, respectivamente.

Conclusiones: La aplicación del gel vaginal basado en *Coriolus versicolor* mejoró significativamente la epitelización del ectocérvix y la composición de la microbiota vaginal en mujeres VPH positivas sin lesiones cervicales, lo que podría apoyar su uso para prevenir las lesiones de cérvix asociadas al VPH.

Palabras clave: Epitelización cérvix, papilomavirus humano, *Lactobacillus*, Papilocare, microbiota vaginal, *Coriolus versicolor*.

Introduction

Human papillomavirus (HPV) is the most common viral infection of the reproductive tract and is mainly transmitted through sexual contact. There is clear evidence linking HPV infection and different types of cancers, including the anus, vulva, vagina, penis and oropharynx^{1,2}. More than 100 types of HPV have been reported, and at least 14 are considered as cancer-causing or high-risk types. Specifically, HPV 16 and 18 account for 70% of all cervical cancers and pre-cancerous lesions worldwide^{3,4}. Despite extensive research, the underlying mechanisms of the HPV life cycle and HPV-induced carcinogenesis have not been fully identified. It is generally accepted that several cofactors, including viral genotype, host immune status, vaginal microbiota and ectocervix histological structure⁵⁻⁷, may regulate a balance between infection and virus clearance. This is crucial for cervical cancer development in HPV-infected women⁸⁻¹¹. Although HPV vaccines are available, they do not protect against all HPV types or established infections^{1,12}, so a more in-depth understanding of the pathological mechanisms of HPV is needed to identify new tools for preventing the infection and development of associated cancers. Regarding vaginal microbiota, several studies have reported an association between abnormalities in its composition (dysbiosis) and the existence of HPV¹³⁻¹⁶. Vaginal dysbiosis has been characterized by a decrease in *Lactobacillus* spp. Beij. (*Lactobacillaceae* family), with a concomitant increase in diversity and anaerobic bacteria abundance, including species of *Gardnerella* Chavan (*Bifidobacteriaceae* family)¹⁷⁻¹⁹.

Considering the histological structure of the ectocervix, it has been reported that a well epithelialized cervix with squamous epithelium and limited or non-existent transformation zone with cellular activity prevents integrative colonization of HPV with oncogenic potential²⁰. Consequently, promoting ectocervix squamous cell epithelialization, which may function as a barrier, seems a plausible approach to hinder HPV integration and prevent infection. In this sense, a non-hormonal vaginal gel based on *Coriolus versicolor* L. (*Polyporaceae* family), Papilocare® (Procure Health, Castelldefels, Barcelona, Spain), has recently been approved in Spain. Its components possess hydrating properties, act as moisturizer and lubricant, enhance and accelerate the repair of atrophic or injured epithelium of the cervicovaginal mucosa, as well as display immunomodulatory effects and restore the balance of the microbiota²¹⁻²⁶. Furthermore, *Coriolus versicolor*, traditionally used in Chinese medicine, has been reported to have antimicrobial, antiviral and anti-tumour properties²⁷. Remarkably, in an open-label prospective pilot study, 21 asymptomatic healthy women were treated with this vaginal gel for 12 consecutive days, and it significantly improved cervical epithelialization while a tendency to improve the dysbiosis status was observed²⁸. These encouraging results prompted us to

evaluate the *Coriolus versicolor*-based vaginal gel in HPV-positive women with normal cytology and colposcopy for a longer period (21 days), by assessing its impact on cervical epithelialization and modulation of vaginal microbiota composition.

Methods

Study design

An observational, non-comparative, open-label, prospective pilot EPICERVIX study included HPV-positive women with negative Papanicolaou smear and normal colposcopy who received treatment with Papilocare® between July 2016 and January 2017 in the Department of Gynaecology at the Obstetrics & Gynaecology Institute (Madrid, Spain). The study was performed under conditions of routine daily practice and in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants. Approval of the study protocol by the institutional review board was not required since studies with a medical device class 1 (not a drug) already marketed and used within approval indications are exempted, according to Spanish law (<http://sid.usal.es/docs/F3/LYN14832/14832.pdf>).

Participants

Inclusion criteria to participate in the study included: sexually active women; aged 25 years or over; attending a routine gynaecological monitoring visit; with diagnosis of HPV by polymerase chain reaction (PCR)-based HPV deoxyribonucleic acid (DNA) detection within three months prior to the consultation; a normal Papanicolaou smear and normal colposcopy findings; and eligible for the prescription of the vaginal gel. Exclusion criteria were: clinically relevant disorders of the immune system or treatment with immunosuppressant agents; abnormal vaginal bleeding (without diagnosis) within the six months prior to the consultation; symptomatic vulvovaginal infection; history of gynaecologic cancer; use of vaginal contraceptives or other vaginal hormonal treatments; scheduled surgery preventing compliance with treatment; participation in another clinical trial; fertile women not using effective contraceptive methods; pregnant or breastfeeding; and contraindication for the use of Papilocare® or known allergies to some of its components.

Study procedures

Women who gave consent to participate in the study and met the inclusion criteria were advised on appropriate use of the vaginal gel Papilocare® according to the patient information leaflet. The gel contains *Coriolus versicolor* as the main component together with niosomes of hyaluronic acid (a moisturizing agent), beta-glucan (an immunomodulator agent), Bioecolia® (a prebiotic agent), phytosomes of *Centella asiatica* L. (*Apiaceae* family) (a tissue regenerating agent), *Azadirachta indica* A. Juss.

(*Meliaceae* family) extract (Neem) (an antioxidant/anti-inflammatory agent), and *Aloe vera* L. (*Asphodelaceae* family) (a re-epithelialization agent). Patients were encouraged to apply Papilocare® once a day before bedtime for 21 consecutive days. The use of douches or vaginal deodorants was not permitted, but sexual activity with or without condom was not limited. Participants found to be eligible, after acceptance for inclusion in the trial, visited the clinic on day 0 (baseline/visit 1) and on day 21 (visit 2). Degree of epithelialization was evaluated colposcopically and samples were obtained to determine the composition of the vaginal microbiota.

Cervical epithelialization

The epithelialization degree of the cervical mucosa was evaluated by the investigator by standard colposcopy and rated using a five-point Likert scale, where five was no ectopy, four: mild (<25% of the external os), three: moderate (25%–50% of the external os), two: severe (>50% of the external os) and one: severe ectopy and bleeding.

Characterization of microbiota

DNA from study samples was isolated as reported elsewhere²⁹. Amplicon fragments were PCR-amplified from the total DNA in duplicate with the Phusion high-fidelity DNA polymerase. A single round of PCR was performed using "fusion primers", targeting 16S rRNA V1-4 region with multiplexing on the Illumina MiSeq machine. PCR products were verified visually by running a high-throughput Invitrogen 96-well-E-gel. The PCR reactions from the same samples were pooled in one plate, then cleaned and normalized using the high-throughput Invitrogen SequalPrep 96-well Plate kit. Samples were then pooled to make one library to be quantified fluorometrically before sequencing. For taxonomic analysis, sequences were selected to estimate the total bacterial diversity of the DNA samples in a comparable manner and were trimmed to remove barcodes, primers, chimeras, plasmids, mitochondrial DNA; in addition to any non-16S bacterial reads and sequences < 150 bp. MG-RAST (metagenomics analysis server)³⁰, with the Ribosomal Database Project (RDP) for analyses of all sequences. The pipeline uses bar coded sequence readings, divides them into individual communities by bar code, makes taxonomic assignments to RDP database with external programmes³¹ and predicts phylogenetic diversity, with a minimum e-value of 1e-5, minimum identity of 60% and a minimum alignment length of 15 measured in base pairs for RNA databases. Each value expressed the percentage relative frequency of readings with predicted proteins and rRNA genes defined for the particular taxonomic level. The output file was also evaluated with SPSS 17.0 Software Package (SPSS Inc., Chicago, Ill, USA) and the Statistical Analysis of Metagenomic Profiles (STAMP) software 2.1.3³².

The composition of bacterial communities was evaluated by calculating three major ecological parameters,

including the Chao1 richness index for abundance data (an estimate of a total community)³³, the Pielou's evenness index (to show how evenly individuals in the community were distributed over different operational taxonomic units (OUT)³⁴, and the Shannon biodiversity index (a combined parameter of richness and evenness)³⁵. The Shannon biodiversity index was categorized as less than two (low diversity), two to three (normal), and more than three (high diversity). Furthermore, a two-dimensional scatterplot was generated by principal coordinates analysis (PCoA) to visualize whether the experimental groups in the input phylogenetic tree had significantly different microbial communities. This method enables visualization of dissimilarities of the data in terms of distance³⁶.


Statistical analysis

Calculation of sample size was unnecessary since the study was exploratory. Quantitative variables were expressed as mean and standard deviation (SD) while categorical variables appeared as frequencies and percentages. Paired samples of continuous data were compared to the Wilcoxon signed-rank test. Data were evaluated using the Power Analysis and Sample Size software programme, version 2011.

Results


A total of 21 patients participated in the study, with a mean age of 38.9 years (range 25-59 years). Microbiota analysis was performed on all women, but cervical epithelialization was analysed in 19 of them. Treatment with the *Coriolus versicolor*-based vaginal gel revealed a beneficial effect on re-epithelialization of the cervix, with median score of 5 (range: 2-5) at the final visit as compared to 4 (range: 2-5) at the onset of the study ($P<0.01$) (Figure 1) and an overall improvement of 18%. Cervix epithelialization improved in 52.6% of women and a score of 5 (no ectopy) was observed in 66.7%, while only 38.1% of the patients had that value at the beginning of the study.

Figure 1: Degree of epithelialization of the cervix mucosa rated by the 5-point Likert scale.




Microbial richness, evenness and diversity, analysed with the Chao, Pielous's and Shannon indices, were significantly decreased at the final visit in comparison with baseline (Figure 2).

Figure 2: Estimate of the phylogenetic diversity of the vaginal microbiota at baseline and after 21 days of treatment with Papilocare® using Chao richness, Pielou evenness and Shannon diversity.



In the PCoA analysis, the composition of vaginal microbial communities clearly differed at the time points evaluated (baseline and end of study) (Figure 3).


Figure 3: Principal component analysis plot based on Bray-Curtis distances.



Moreover, there was a notable change of abundance in the most representative phyla. At baseline, the predominant phylum was *Proteobacteria* (93.6%) with a lower proportion of bacteria belonging to the phyla *Actinobacteria*, *Bacteroidetes* and *Firmicutes* (1.5%, 2.4% and 2.1%, respectively). At the end of the treatment, a statistically significantly ($P < 0.005$) higher proportion of the phyla *Firmicutes* (44.6%), to which *Lactobacilli* belongs,


was observed, together with a decrease in the phylum *Proteobacteria* (38.5%), which includes a large number of potential pathogens (Figure 4).

Figure 4: Proportions of the different phyla of bacteria in the ectocervix samples at baseline and at the end of the study after 21 days of treatment with Papilocare®



Finally, at the end of treatment, statistically significant increases ($P < 0.05$) in comparison with baseline were documented for *L. iners* and *L. crispatus*. However, other species, such as *Gardnerella vaginalis* decreased significantly (Figure 5).

Figure 5: Individual proportions of *Lactobacillus iners* and *crispatus* and *Gardnerella vaginalis* at baseline and after 21 days of treatment with Papilocare®



Discussion

This study performed on HPV-positive women revealed that once-daily vaginal application of Papilocare® for 21 consecutive days had a favourable effect on cervix epithelialization and vaginal microbiota. These findings, although obtained in a small study population, are clinically relevant since the moisturizing, repairing and epithelizing properties of the vaginal gel, as well as its effect restoring the balance of vaginal microbiota could contribute to prevent the clinical course of HPV-associated lesions.

The cervix has a very unstable histological structure with permanent confrontation of the scaly vaginal strata and the cylindrical endocervical glandular epithelium. Below this glandular epithelium there is a lining consisting of 'reserve' cells that retain the ability to grow and differentiate into mature forms of squamous or glandular epithelium. This process has been called metaplasia and generates an area identified in the cervix as a 'transformation zone'. This is a common process in sexually active women, especially in those using hormonal contraceptives or intra-uterine devices and in women who have given birth. The reserve cells in the metaplastic process of re-epithelialization fulfil this condition and are perfect targets for the anchoring of HPV^{37,38} since HPV needs to integrate into mitotically active cells²⁰. Thus, the preservation of a well epithelized cervical neck and an extended transformation zone would prevent the integrative colonization of HPV. Therefore, the reported effects of Papilocare® in repairing, stimulating squamous epithelialization and remodelling the transformation zone may have an important indirect role in reducing the susceptibility of the cervix to HPV infection. Moreover, and although it has not been explored in this study, *Coriolus versicolor* has been reported to have immunostimulatory properties that mediate the clearance of oral HPV³⁹ and might control the proliferation of malignancies⁴⁰.

Moreover, the vaginal microbiota plays a significant role in the health and disease of the female reproductive tract. Next-generation sequencing techniques based upon analysis of bacterial 16S rRNA genes enable in-depth study of the vaginal microbial community structure, which is not possible with standard culture-based microbiological techniques. There is emerging evidence that increased diversity of vaginal microbiota together with reduced relative abundance of *Lactobacillus* spp. is involved in HPV acquisition and persistence⁷. Actually, a recent study of women with low- and high-grade cervical dysplasia and invasive cervical carcinoma, revealed that elevated vaginal pH and decreased *Lactobacillus* dominance were associated with severity of the cervical neoplasm⁴¹. Furthermore, a dysbiotic, non-*Lactobacillus*-dominant and highly diverse vaginal microbiota has been linked to the increasing severity of precancerous cervical intraepithelial neoplasia (CIN)¹⁶. Interestingly, the HPV-positive women recruited to the study presented a

dysbiotic vaginal microbiota dominated by *Proteobacteria* and with a reduced abundance of *Firmicutes*. The results in this study revealed that treatment with Papilocare vaginal gel led to a shift towards the vaginal microbiota composition found in healthy women, with a reduction in microbial abundance, evenness and diversity. Moreover, the treatment significantly reduced the abundance of species associated with HPV infection such as *Gardnerella vaginalis*⁴² and increased the proportion of *Lactobacillus* spp. Currently, *Lactobacillus* depletion is a well-known feature of vaginal dysbiosis and abnormal vaginal microbiome⁴³. These results are in accordance with our previous study in which gel-treatment of asymptomatic healthy women improved vaginal dysbiosis²⁸.

These results should be interpreted considering the exploratory pilot nature of the study, the single-centre and open label design and especially the short-term use of the vaginal gel product. Nevertheless, HPV-positive women without cytological and colposcopy abnormalities were carefully selected and, to the best of our knowledge, this is the first study to assess cervical re-epithelialization and changes in the vaginal microbiota associated with the use of a natural hydrating and moisturizing gel; whose components have proven anti-inflammatory, epithelizing and immunomodulatory effects, together with the capacity to preserve the vaginal microbiota balance. These encouraging preliminary findings provide the basis for designing an investigational plan involving clinical trials and observational studies, which is currently underway. Subsequently, confirmatory data will support its potential use in HPV-positive patients. In addition, this product will have the advantage of an easy and convenient administration protocol.

In conclusion, Papilocare® significantly improved cervix epithelialization among HPV-positive women without cervical lesions. The higher abundance of specific species of the genus *Lactobacillus* after the treatment suggests a restoration of the altered microbiota composition in these women. These results might account for the mechanisms of action of Papilocare® underlying its positive effects on repairing cervical lesions.

Funding

This work was partially supported by the Regional Government of Andalusia (CTS 164) and by Carlos III Healthcare Institute (PI19/01058) with funds from the European Union. CIBER-EHD is funded by the Carlos III Healthcare Institute. Procare Health (Castelldefels, Barcelona, Spain) provided logistic support for the study but had no role in design of the study, collection, analysis, and interpretation of data and in drawing up the manuscript.

Authors' Contributions

Conceptualization, S.G., L.S., J.C., A.R.N and J.G.; methodology, T.V., J.G-M., F.A., R.M. and M.E.R.C.; validation, A.R.N. and J.G.; resources, J.C., L.S. and J.G.; writing-original draft preparation, M.E.R.C., J.G. and A.R.N.; writing-review and editing, T.V., J.G. and A.R.N.; supervision and funding acquisition, J.C., J.G.

and A.R.N. All authors have read and agree with the published version of the manuscript.

Interests conflict

J.C., S.G. and L.S. have been speakers at Procure Health events in several conferences. The remaining authors have no conflict of interest to declare.

References

1. Facts C. American Cancer Society. Cancer Facts & Figures 2009. Atlanta: American Cancer Society; 2009.
2. Krzowska-Firych J, Lucas G, Lucas C, Lucas N, Pietrzyk Ł. An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. *J Infect Public Health*. 2019; 12(1): 1-6.
3. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). human papillomavirus and related diseases in the world. Summary report 27 July 2017. 2018.
4. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol*. 2002; 55(4): 244-65.
5. Wang SS, Hildesheim A. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. *J Natl Cancer Inst Monogr*. 2003; (31): 35-40.
6. Doeberitz M, Vinokurova S. Host factors in HPV-related carcinogenesis: cellular mechanisms controlling HPV infections. *Arch Med Res*. 2009; 40(6): 435-42.
7. Mitra A, MacIntyre DA, Marchesi JR, Lee YS, Bennett PR, Kyrgiou M. The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? *Microbiome* 2016; 4(1): 58.
8. Syrjänen K. Mechanisms and predictors of high-risk human papillomavirus (HPV) clearance in the uterine cervix. *Eur J Gynaecol Oncol*. 2007; 28(5): 337-51.
9. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, et al. Updating the natural history of human papillomavirus and anogenital cancers. *Vaccine* 2012; 30 Suppl 5: F24-33.
10. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. *Trends Microbiol*. 2011; 19(1): 33-9.
11. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. *Prev Med*. 2011; 53 Suppl 1: S12-21.
12. Arbyn M, Xu L, Simoons-Sch C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. *Cochrane Database Syst Rev*. 2018; 5: CD009069.
13. Gillet E, Meys JF, Verstraeten H, Bosire C, De Sutter P, Temmerman M, et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. *BMC Infect Dis*. 2011; 11: 10.
14. Kyrgiou M, Mitra A, Moscicki AB. Does the vaginal microbiota play a role in the development of cervical cancer? *Transl Res*. 2017; 179: 168-82.
15. Audirac-Chalifour A, Torres-Poveda K, Bahena-Roman M, Tellez-Sosa J, Martinez-Barnette J, Cortina-Ceballos B, et al. Cervical Microbiome and Cytokine Profile at Various Stages of Cervical Cancer: A Pilot Study. *PLoS one* 2016; 11(4): e0153274.
16. Mitra A, MacIntyre DA, Lee YS, Smith A, Marchesi JR, Lehne B, et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. *Sci Reports* 2015; 5: 16865.
17. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med*. 2005; 353(18): 1899-911.
18. Gao W, Weng J, Gao Y, Chen X. Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study. *BMC Infect Dis*. 2013; 13: 271.
19. Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. *PLoS one* 2013; 8(5): e63514.
20. Hwang LY, Ma Y, Shiboski SC, Farhat S, Jonte J, Moscicki AB. Active squamous metaplasia of the cervical epithelium is associated with subsequent acquisition of human papillomavirus 16 infection among healthy young women. *J Infect Dis*. 2012; 206(4): 504-11.
21. Chu KK, Ho SS, Chow AH. *Coriolus versicolor*: a medicinal mushroom with promising immunotherapeutic values. *J Clin Pharmacol*. 2002; 42(9): 976-84.
22. Møller MS, Goh YJ, Viborg AH, Andersen JM, Klæenhammer TR, Svensson B, et al. Recent insight in α -glucan metabolism in probiotic bacteria. *Biologia* 2014; 69: 713-21.
23. Shukla S, Bharti AC, Hussain S, Mahata S, Hedau S, Kailash U, et al. Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. *J Cancer Res Clin Oncol*. 2009; 135(12): 1701-9.
24. Bylka W, Znajdek-Awizien P, Studzińska-Sroka E, Danczak-Pazdrowska A, Brzezinska M. *Centella asiatica* in dermatology: an overview. *Phytother Res*. 2014; 28(8): 1117-24.

25. Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. *J Sex Med.* 2013; 10(6): 1575-84.
26. Radha MH, Laxmipriya NP. Evaluation of biological properties and clinical effectiveness of Aloe vera: A systematic review. *J Tradit Complement Med.* 2015; 5(1): 21-6.
27. Saleh MH, Rashedi I, Keating A. Immunomodulatory Properties of *Coriolus versicolor*: The Role of Polysaccharopeptide. *Front Immunol.* 2017; 8: 1087.
28. Palacios S, Losa F, Dexeus D, Cortes J. Beneficial effects of a *Coriolus versicolor*-based vaginal gel on cervical epithelialization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women. *BMC Women's Health* 2017; 17(1): 21.
29. Rodriguez-Nogales A, Algieri F, Garrido-Mesa J, Vezza T, Utrilla MP, Chueca N, et al. Differential intestinal anti-inflammatory effects of *Lactobacillus fermentum* and *Lactobacillus salivarius* in DSS mouse colitis: impact on microRNAs expression and microbiota composition. *Mol Nutr Food Res.* 2017; 61(11).
30. Meyer F, Paarmann D, D'Souza M, Olson R, Glass EM, Kubal M, et al. The metagenomics RAST server - a public resource for the automatic phylogenetic and functional analysis of metagenomes. *BMC bioinformatics* 2008; 9: 386.
31. Wang Q, Garrity GM, Tiedje JM, Cole JR. Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol.* 2007; 73(16): 5261-7.
32. Parks DH, Tyson GW, Hugenholtz P, Beiko RG. STAMP: statistical analysis of taxonomic and functional profiles. *Bioinformatics* 2014; 30(21): 3123-2134.
33. Chao A. Nonparametric estimation of the number of classes in a population. *Scand J Statist.* 1984: 265-70.
34. Pielou EC. The measurement of diversity in different types of biological collections. *J Theor Biol.* 1966; 13: 131-44.
35. Shannon C. A mathematical theory of communication. *J Bell Syst Tech.* 1948; 27(3): 379-423.
36. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* 2010; 7(5): 335-6.
37. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. *Cancer Epidemiol Biomarkers Prev.* 2013; 22(4): 553-60.
38. Rocha-Zavaleta L, Yescas G, Cruz RM, Cruz-Talonia F. Human papillomavirus infection and cervical ectopy. *Int J Gynaecol Obstet.* 2004; 85(3): 259-66.
39. Donatini B. Control of oral human papillomavirus (HPV) by medicinal mushrooms, *Trametes versicolor* and *Ganoderma lucidum*: a preliminary clinical trial. *Int J Med Mushrooms.* 2014; 16(5): 497-8.
40. Mao XW, Green LM, Gridley DS. Evaluation of polysaccharopeptide effects against C6 glioma in combination with radiation. *Oncology* 2001; 61(3): 243-53.
41. Laniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM, et al. Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women. *Sci Rep.* 2018; 8(1): 7593.
42. Murta EF, Souza MA, Araujo Junior E, Adad SJ. Incidence of *Gardnerella vaginalis*, *Candida* sp and human papilloma virus in cytological smears. *Sao Paulo Med J.* 2000; 118(4): 105-8.
43. Mendling W. Vaginal microbiota. *Adv Exp Med Biol.* 2016; 902: 83-93.



www.ramib.org

Junta Directiva de la Reial Acadèmia de Medicina de les Illes Balears

President Macià Tomàs Salvà
Vicepresident Àngel Arturo López González
Secretari General Antonio Cañellas Trobat
Vicesecretari Sebastian Crespí Rotger
Tresorer Joan Besalduch Vidal
Bibliotecària Antonia Barceló Bennasar

Acadèmics d'honor

2003 - Excm. Sr. Santiago Grisolia García, Premi Príncep d'Astúries
2007 - Excm. Sr. Ciril Rozman, Premi Jaime I

Acadèmics numeraris

M. I. Sra. Juana M. Román Piñana
M. I. Sr. Josep Tomàs Monserrat
M. I. Sr. Bartomeu Anguera Sansó
M. I. Sr. Bartomeu Nadal Moncadas
M. I. Sr. Alfonso Ballesteros Fernández
M. I. Sr. Ferran Tolosa i Cabaní
Excm. Sr. Macià Tomàs Salvà
M. I. Sra. Joana M. Sureda Trujillo
M. I. Sr. Joan Buades Reinés
M. I. Sr. José L. Olea Vallejo
M. I. Sr. Pere Riutord Sbert
M. I. Sr. Joan Besalduch Vidal
M. I. Sr. Fèlix Grases Freixedas
M. I. Sr. Antoni Cañellas Trobat
M. I. Sr. Josep Francesc Forteza Albertí
M. I. Sr. Jordi Ibáñez Juvé
M. I. Sr. Joan March Noguera
M. I. Sr. Àngel Arturo López González
M. I. Sra. Pilar Roca Salom
M. I. Sr. Javier Cortés Bordoy
M. I. Sr. Lluís Masmiquel Comas
M. I. Sr. Sebastià Crespí Rotger
M. I. Sra. Antònia Barceló Bennassar
M. I. Sr. Javier Garau Alemany
M. I. Sr. Jordi Reina Prieto
M. I. Sr. Joan M. Benejam Gual
M. I. Sr. Claudio Rubén Mirasso Santos
M. I. Sr. Josep M^a Vicens Gómez
M. I. Sr. Rafael Morales Soriano

Acadèmics supernumeraris

M.I. Sr. Àlvar Agustí García-Navarro
M.I. Sra. Marta Emma Couce Matovelle

Acadèmics emèrits

M.I. Sr. Arnau Casellas Bernat



www.ramib.org

Protectors de la Reial Acadèmia

Banca March
Conselleria de Presidència
ASISA
Conselleria de Salut
Col·legi Oficial de Metges de les Illes Balears
Fundació Patronat Científic del Col·legi de Metges de les Illes Balears

Benefactors de la Reial Acadèmia

Salut i Força

Patrocinadors de la Reial Acadèmia

Clínica Rotger
Metges Rosselló
Grup Hospitalari Quirónsalud
Col·legi Oficial d'Infermeria de les Illes Balears
Associació Espanyola contra el Càncer a les Illes Balears
Col·legi Oficial de Farmacèutics de Balears
Escola Universitària ADEMA

ACADEMIC JOURNAL
OF HEALTH SCIENCES

MEDICINA BALEAR

www.medicinabaleaer.org